RESUMEN
Nonalcoholic fatty liver disease (NAFLD) is prevalent in obese patients. We sought to determine the effects of bariatric surgery on the histological features of NAFLD. Two blinded pathologists graded liver biopsies done during bariatric procedures and subsequent operations in 160 patients using the Brunt classification. Data are mean ± SD. Interval between biopsies was 31 ± 26 months. Initial biopsies demonstrated steatosis 77 %, lobular inflammation 39 %, and chronic portal inflammation 56 %. Steatohepatitis was present in 27 %. Grade 2-3 fibrosis was present in 27 %, and cirrhosis was present in one patient. On post-bariatric biopsy, steatosis resolved in 75 %, lobular inflammation resolved in 75 %, chronic portal inflammation resolved in 49 %, and steatohepatitis resolved in 90 %. Fibrosis of any grade resolved in 53 % and improved in another 3 % of patients. Grade 2 fibrosis resolved in 58 %, improved in 3 %, and did not worsen in 11 %. Bridging fibrosis resolved in 29 %, improved in 29 %, and did not worsen in 29 %. Bariatric surgery is associated with resolution of steatosis or steatohepatitis in the majority of patients. More importantly, grade 2 or 3 (bridging) fibrosis is resolved or improved in 60 % of patients. Bariatric surgery should be considered as a treatment of NAFLD in severely obese patients.
Asunto(s)
Cirugía Bariátrica , Hepatitis/patología , Cirrosis Hepática/patología , Hígado/patología , Enfermedad del Hígado Graso no Alcohólico/patología , Obesidad Mórbida/cirugía , Adulto , Anciano , Biopsia , Femenino , Hepatitis/complicaciones , Humanos , Cirrosis Hepática/complicaciones , Masculino , Persona de Mediana Edad , Enfermedad del Hígado Graso no Alcohólico/complicaciones , Obesidad Mórbida/complicaciones , Prevalencia , Método Simple Ciego , Adulto JovenRESUMEN
BACKGROUND: A 74-year-old woman with a history of type I cryoglobulinemia with glomerulonephritis that had been successfully treated with plasmapheresis and cyclophosphamide approximately 9 years earlier presented with hemoptysis and mediastinal lymphadenopathy. Evaluation revealed the reappearance of cryoglobulins and nephrotic-range proteinuria. In addition, the patient's serum creatinine level, which had been stable for approximately 9 years after her first treatment, had increased from 79.2 micromol/l (0.9 mg/dl) to 281.6 micromol/l (3.2 mg/dl) over 6 months. INVESTIGATIONS: Physical examination, serum and urine laboratory analyses, CT scan, mediastinoscopy with lymph node biopsy, bone marrow biopsy, flow cytometry analysis of bone marrow, peripheral blood and lymph node tissue, and percutaneous ultrasound-guided renal biopsy. DIAGNOSIS: Type I cryoglobulinemic glomerulonephritis associated with a CD20(+) lymphoid disorder. MANAGEMENT: One plasmapheresis treatment, one dose of cyclophosphamide, and four weekly cycles of rituximab.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Crioglobulinemia/tratamiento farmacológico , Glomerulonefritis/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Anticuerpos Monoclonales de Origen Murino , Antígenos CD20 , Biopsia , Crioglobulinemia/diagnóstico , Crioglobulinemia/metabolismo , Femenino , Estudios de Seguimiento , Glomerulonefritis/complicaciones , Glomerulonefritis/diagnóstico , Humanos , Riñón/patología , Persona de Mediana Edad , Rituximab , Índice de Severidad de la EnfermedadRESUMEN
This placebo-controlled, randomized, multicenter trial compared the effects of MTX plus UDCA to UDCA alone on the course of primary biliary cirrhosis (PBC). Two hundred and sixty five AMA positive patients without ascites, variceal bleeding, or encephalopathy; a serum bilirubin less than 3 mg/dL; serum albumin 3 g/dL or greater, who had taken UDCA 15 mg/kg daily for at least 6 months, were stratified by Ludwig's histological staging and then randomized to MTX 15 mg/m2 body surface area (maximum dose 20 mg) once a week while continuing on UDCA. The median time from randomization to closure of the study was 7.6 years (range: 4.6-8.8 years). Treatment failure was defined as death without liver transplantation; transplantation; variceal bleeding; development of ascites, encephalopathy, or varices; a doubling of serum bilirubin to 2.5 mg/dL or greater; a fall in serum albumin to 2.5 g/dL or less; histological progression by at least two stages or to cirrhosis. Patients were continued on treatment despite failure of treatment, unless transplantation ensued, drug toxicity necessitated withdrawal, or the patient developed a cancer. There were no significant differences in these parameters nor to the time of development of treatment failures observed for patients taking UDCA plus MTX, or UDCA plus placebo. The trial was conducted with a stopping rule, and was stopped early by the National Institutes of Health at the advice of our Data Safety Monitoring Board for reasons of futility. In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone.